Gene therapy for wet AMD passes early safety check in small study
Disease control
Ongoing
This study checks the long-term safety of a gene therapy called EXG102-031 for people with wet age-related macular degeneration (AMD), a condition that causes blurry or lost central vision. Twelve people who already received the gene therapy in an earlier study will be followed f…
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC